Thyroid disease

Progression of Nodular Thyroid Disease in Familial Adenomatous Polyposis Syndrome: Refined Surveillance Recommendations

Endocr PractPublished Retrospective cohort study

Authors' conclusion

Based on the Kaplan-Meier analysis, ongoing longitudinal screening is warranted for patients with FAP as they are prone to thyroid cancer and nodule development overtime even when presenting with a baseline normal US. Additionally, these data demonstrate a slow development of thyroid cancer from a normal US, thus it is reasonable to consider selectively extending the screening interval for this population.

Study context

Population
Patients with familial adenomatous polyposis (FAP) undergoing screening thyroid ultrasound (US), 2008–2023; 50% male, median age at first screening 38 years80% longitudinal follow-up
Participants
556 patients
Outcome
Disease progression on serial US: development of new nodules and cancer
Methodological detailssingle referral center, Kaplan-Meier analysis
  • Single referral center
  • Kaplan-Meier analysis

Main finding

As reported in the abstract

Cumulative incidence of initial and subsequent thyroid cancer and of thyroid nodules (Kaplan-Meier) · median follow-up 7 years
Cumulative incidence of thyroid cancer by 5 years
4%
Cumulative incidence of thyroid cancer by 10 years
6%
Cumulative incidence of thyroid nodules by 5 years
40%
Cumulative incidence of thyroid nodules by 10 years
48%
Diagnosed with thyroid cancer
20 patients (3.6%)
Normal baseline US who developed a nodule over time
14%

Observational data: associations, not effects.

Further findings

Nodules at initial screening

Patients with nodules
169 (30%)

Original publication

Progression of Nodular Thyroid Disease in Familial Adenomatous Polyposis Syndrome: Refined Surveillance Recommendations. Endocr Pract. Published 21 May 2024. doi:10.1016/j.eprac.2024.05.007

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.